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Amavata is one such disease where in authors 
categorized the pain as Vrischikadamshavata 
Vedana.[1] It is a chronic condition involving loss of 
mobility and enduring pain of the joints with some 
swelling of the synovial joints. Amavata has 
similarities to many arthritic diseases with specific 
clinical  features  associated with Rheumatoid Arthritis  
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(RA).[2] Rheumatoid arthritis is a joint disorder which 
affects multiple joints at various sites. RA is a chronic 
systemic inflammatory disease. Persistent synovial 
inflammation often causes cartilage damage and bone 
erosions that badly disturbs joint integrity, as an 
outcome of which one third of patients suffer from 
working disability by five years.[3] RA is correlated 
with Amavata mentioned in Ayurveda. Amavata is a 
particular type of disease that is mentioned in 
Ayurveda since the period of Madhav, under the 
category of Vata-Kaphaja disorder. In spite of the 
description of multiple drug therapy on Amavata in 
different classics of Ayurveda, potential and durable 
results are not found due to non-removal of the basic 
cause. Hence, special emphasis should be put into 
searching for a standard and suitable drug 
for Amavata. In Amavata, Vata is dominant Dosha 
and Ama is the chief pathogenic factor. Ancient 
Acharyas of Ayurveda has described sequential 
employment of Deepana, Pachana, Shodhana and 
Shamana therapies in the management of Amavata.[4] 
A B S T R A C T  
In Ayurvedic text book, Amavata symptom is mentioned as swelling, joint pain, numbness, appetite 
loss, indigestion and fever. In Charaka Samhita and Sushruta Samhita, Amavata is mentioned as a 
syndrome called Vatavyadhi, a diverse group of symptoms that are organized according to the 
systemic and local manifestations of Vata Dosha. According to the Charaka Samhita of Vatavyadhi, 
when Vata affects the Asthi and Majja there is painful swelling and immobility of the joints. Hence 
clinical study is planned to evaluate effect of Alambushadi Churna and in the Management of Amavata 
for that 60 Patients having classical symptomatology of Amavata have been selected from 
Kayachikitsa OPD and IPD of Sir Sunder Lal Hospital, Institute of Medical Sciences, Banaras Hindu 
University, Varanasi and divided in two groups. Results of study shows that the sign and symptoms 
e.g., Loss of appetite, Angamarda, Alasya etc. due to derangement of Aam are observed to be 
improved in by Alambushadi Churna oral dose compared to Methotrexate. 
Key words: Alambushadi Churna, Dwipanchmuladya Taila Basti, Amavata, Aam, Rheumatoid 
Arthritis. 
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The rheumatological disorder is a group of diseases 
that has no specific medical management in any type 
of therapeutics. Anti-inflammatory, analgesic, steroids 
and disease modified anti rheumatic drug are 
required for its management which are not free from 
its side effect. Many Ayurvedic formulations are 
carried to be effective in Amavata however scientific 
evidence need to be produced, though ample 
research work has been done on disease Amavata but 
satisfactory result has not been obtained till date. 
Hence to establish a firm scientific basis for classical 
Ayurvedic formulation is now being felt. The 
formulations under trial in this study, Alambushadi 
Churna is described in the Ayurvedic Text in 
Chakradatta Amavataadhikara.[5]  The selected trial 
drug Alambusadi Churna is mentioned by Acharya 
Chakrapani in Chakradatta in reference to Amavata 
Rogadhikara. Alambushadi Churna is given by oral 
route. Also Matra Basti with Dwipanchmuladya Taila 
is described in the Ayurvedic Text in Chakradatta 
Niruhadhikara.[6] In present study Basti Karma was 
selected as Shodhana Chikitsa. It is directly mentioned 
in the Chikitsa Sutra of Amavata by Chakradatta and 
is considered as Ardha Chikitsa in Ayurvedic texts. 
Design of the study: The study is open-labelled, 
randomized clinical study.  
AIMS AND OBJECTIVES 
1. To clinically assess the efficacy of Alambusadi 
Churna in the management Amavata vis-à-vis 
Rheumatoid arthritis. 
2. To clinically assess the efficacy of 
Dwipanchmuladya Tail Basti in the management 
of Amavata  
3. To compare the clinical efficacy of Interventional 
group and modern Control group in the 
management Amavata vis-à-vis Rheumatoid 
arthritis. 
MATERIALS AND METHODS  
Preparation of drugs 
▪ All the crude drugs were available in pharmacy of 
Rasa Sastra department. All drugs were tested for 
their quality and authenticity. Alambushadi 
Churna was prepared following the SOP norms as 
follows-  
▪ Starting from Lajjalu, all the drugs up to Trivrita in 
given quantity were mixed and made into fine 
Churna (powder).  
Table 1: Contents of Alambushadi Churna. 
SN Name Botanical Name Quantity 
1. Lajjalu Mimosa pudica 1 part 
2. Gokshur Tribulus terrestris 2 part 
3. Amalaki Emblica officinalis 3 part 
4. Haritki Terminalia chebula 4 part 
5. Bibhitki Terminalia bellirica 5 part 
6. Sunthi Zingiber officinalis 6 part 
7. Guduchi Tinosporacardifolia 7 part 
8. Trivrita Operculinaturpethum 28 part 
Preparation of Basti 
Table 1: Contents of Dwipanchmuladya Tail Basti 
SN Name Botanical name Quantity 
1. Belmul twak Aegle marmelos 1 part 
2. Gambharimultwak Gmelia arborea 1 part 
3. Patalamul) Stereospermum 
suaveolens 
1 Pala  
4. Sonapatha Oroxylum Indicum 1 part 
5. Arnimul Premna mucronata 1 part 
6. Shalparni Desmodium 
gangeticum 
1 part 
7. Prishnaiparni Uraria picta 1 part 
8. Chotkatari Solanum Surattense 1 part 
9. Badikatari Solanum Indicum 1 part 
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10. Gokshur Tribulus Terrestris 1 part 
11. Tilataila Sesame Oil Q.S. 
Method of preparation 
All the crude drugs were available in pharmacy of 
Rasasastra department. All drugs were tested for 
their quality and authenticity. Dwipanchmuladya Taila 
was prepared according to Ayurvedic Classic Text 
Book. 
Time of administration 
It is a Matra Basti that can be given after the meals 
(Bhukte Cha Api Pradiyate). 
Method of administration of Basti 
Patient was advised to lie on an even Basti table in left 
lateral position with straight body and left hand kept 
as pillow. His right leg was folded at knee joint and 
made to rest flat over the left leg. Patient’s anus and 
rubber catheter was smeared with oily substance like 
tail. Rubber catheter was introduced in anus by its 4-
6cm part slowly. Bastidravya was taken in Asep to 
pump and forced slowly in one push then after 
Rubber catheter was taken out slowly.[7]    
Selection of cases 
Total 60 patients of Amavata were randomly selected 
and divided in 4 groups for the present study, from 
the Kayachikitsa OPD and IPD of Sir Sunder Lal 
Hospital, Institute of Medical Sciences, Banaras Hindu 
University, Varanasi. The case selection was random 
regardless of age, sex, occupation and religion. Both 
acute and chronic phase of Amavata patients were 
taken for the study, following the criteria of the 
diagnosis of Rheumatoid Arthritis in Modern Medicine 
and the clinical features of Amavata described in 
Madhava Nidana.  
Inclusion criteria 
▪ Age between 20-60 years. 
▪ Diagnosed cases of Amavata based on symptoms 
and signs described in Nidana and EULAR 2010. 
▪ Sero positive and sero negative both cases are 
included. 
▪ Patients with H/O 1-5 years with established 
disease.  
Exclusion criteria 
▪ Patients should not be less than 20 year and more 
than 60 year. 
▪ Patients of Rheumatic Arthritis, Gouty Arthritis, 
Septic Arthritis, Osteoarthritis and Ankylosing 
Spondylitis. 
▪ HIV, Tuberculosis, Hypertension, D.M. and other 
systemic problem. 
▪ Pregnant and lactating women. 
Diagnostic criteria for rheumatoid arthritis 
Modern diagnosis is done by the 1987 revised criteria 
by American college of Rheumatology for diagnosis of 
Rheumatoid arthritis and Anti-CCP antibody Ayurvedic 
diagnosis of Amavata was made on the basis of 
symptom of Amavata described in Ayurvedic text 
book. After thoroughly studied and all the sign and 
symptoms has been taken into consideration. Among 
them all the cardinal symptoms have been analysed 
before and after the treatment. 
Study design 
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Parameters for the assessment of improvement  
The effect of therapeutic regimen was assessed with 
the help of certain parameters stating the clinical, 
biochemical, and immunological status of the disease. 
Follow up findings were compared with the initial / 
basal observations and the data subjected to the 
suitable statistical analysis. 
Following parameters were selected as the criteria for 
assessing the improvement. 
▪ Assessment change of functional status and 
physiological factors of these patients before and 
after the treatment. 
▪ Clinical assessment of disease severity. This is 
done by estimating the severity in specific 
symptoms of disease and joint inflammation 
index. 
▪ Laboratory investigations conducted before, 
during follow ups and after the treatment. 
Clinical assessment of Amavata  
A. Assessment of functional status  
1. Walking time 
2. Grip power and pressing power 
3. Foot pressure 
B. Clinical assessment of the disease  
Clinical assessment of the disease, its severity, extent 
and grades of inflammation were objectively done in 
terms of pain swelling tenderness, deformity, general 




4. General Function Capacity 
5. Tenderness 
C. Haematological investigations - Anti CCP, EULAR 
and RA. 
OBSERVATION AND RESULTS  
Table 2: Pain 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.0 0 0.0 0 0.0 0 0.0 2=37.554 
p=0.000 
1 0 0.0 0 0.0 0 0.0 4 30.8 
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2 0 0.0 0 0.0 6 46.2 5 38.5 
3 5 38.5 6 46.2 7 53.8 4 30.8 
4 8 61.5 7 53.8 0 0.0 0 0.0 
B 0 0 0.0 0 0.0 0 0.0 0 0.0 2=32.556 
p=0.000 
1 0 0.0 0 0.0 0 0.0 5 41.7 
2 0 0.0 2 16.7 5 41.7 6 50.0 
3 3 25.0 7 58.3 7 58.3 1 8.3 
4 9 75.0 3 25.0 0 0.0 0 0.0 
C 0 0 0.0 0 0.0 0 0.0 5 38.5 2=37.331 
p=0.000 
1 0 0.0 0 0.0 3 23.1 7 53.8 
2 0 0.0 4 30.8 8 61.5 1 7.7 
3 6 46.2 8 61.5 2 15.4 0 0.0 
4 7 53.8 1 7.7 0 0.0 0 0.00 
D 0 0 0.0 0 0.0 0 0.0 8 61.5 2=37.984 
p=0.000 
1 0 0.0 0 0.0 7 53.8 5 38.5 
2 0 0.0 2 15.4 6 46.2 0 0.0 
3 6 46.2 9 69.2 0 0.0 0 0.0 
4 7 53.8 2 15.4 0 0.0 0 0.0 
Inter group comparison 
among the groups 













Table 3: Swelling 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.00 0 0.00 0 0.00 3 23.1 2=35.605 
p=0.000 
1 0 0.00 0 0.00 4 30.8 9 69.2 
2 4 30.8 7 53.8 9 69.2 1 7.7 
Sunil Kumar et al. Comparative clinical study in the management of Amavata 
ISSN: 2456-3110                                                   ORIGINAL ARTICLE Nov-Dec 2020 
 
Journal of Ayurveda and Integrated Medical Sciences | Nov - Dec  2020 | Vol. 5 | Issue 6 25 
 
3 9 69.2 6 46.2 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 1 8.3 2=30.810 
p=0.000 
1 0 0.00 0 0.00 5 41.7 8 66.7 
2 3 25.0 9 75.0 7 58.3 3 25.0 
3 9 75.0 3 25.0 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 0 0.00 9 69.2 2 =36.378 
p=0.000 
1 0 0.00 0 0.00 9 69.2 4 30.8 
2 5 38.5 11 84.6 4 30.8 0 0.00 
3 8 61.5 2 15.4 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 8 61.5 2=35.845 
p=0.000 
1 0 0.00 1 7.7 10 76.9 5 38.5 
2 5 38.5 9 69.2 3 23.1 0 0.00 
3 8 61.5 3 23.1 0 0.00 0 0.00 
Inter group comparison 
among the groups 










Table 4: Joint Stiffness 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=34.189 
p=0.000 
1 0 0.00 0 0.00 5 38.5 9 69.2 
2 4 30.8 9 69.2 8 61.5 3 23.1 
3 9 69.2 4 30.8 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 2 16.7 2=28.372 
p=0.000 
1 0 0.00 1 8.3 8 66.7 8 66.7 
2 6 50.0 10 83.3 3 25.0 2 16.7 
3 6 50.0 1 8.3 1 8.3 0 0.00 
C 0 0 0.00 0 0.00 0 0.00 5 38.5 2=34.902 
p=0.000 
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 1 0 0.00 1 7.7 9 69.2 8 61.5  
2 7 53.8 9 69.2 4 30.8 0 0.00 
3 6 46.2 3 23.1 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 5 38.5 2= 35.690 
p=0.000 
1 0 0.00 1 7.7 11 84.6 8 61.5 
2 4 30.8 10 76.9 2 15.4 0 0.00 
3 9 69.2 2 15.4 0 0.00 0 0.00 
Inter group comparison 
among the groups 










Table 5: Walking Time 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=34.091 
p=0.000 
1 0 0.00 0 0.00 8 61.5 11 84.6 
2 5 38.5 11 84.6 5 38.5 1 7.7 
3 8 61.5 2 15.4 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 4 33.3 2=32.774 
p=0.000 
1 0 0.00 0 0.00 9 75.0 8 66.7 
2 6 50.0 11 91.7 3 25.0 0 0.00 
3 6 50.0 1 8.3 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 2 15.4 10 76.9 2=35.619 
p=0.000 
1 1 7.7 3 23.1 9 69.2 3 23.1 
2 6 46.2 10 76.9 2 15.4 0 0.00 
3 6 46.2 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 10 76.9 2=36.885 
p=0.000 
1 0 0.00 1 7.7 11 84.6 3 23.1 
2 5 38.5 11 84.6 2 15.4 0 0.00 
3 8 61.5 1 7.7 0 0.00 0 0.00  
Inter group comparison 2=1.257 2=6.771 2=3.901 2=18.437 
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among the groups 
Kruskal Wallis test 
P=0.739 P=0.80 P=0.272 P=0.000 
Table 6: Grip Power 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=33.956 
p=0.000 
1 0 0.00 1 7.7 6 46.2 12 92.3 
2 5 38.5 10 76.9 7 53.8 0 0.00 
3 8 61.5 2 15.4 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 1 8.3 2=31.912 
p=0.000 
1 0 0.00 0 0.00 8 66.7 10 83.3 
2 6 50.0 11 91.7 4 33.2 1 8.3 
3 6 50.0 1 8.3 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 0 0.00 7 53.8 2=35.619 
p=0.000 
1 0 0.00 1 7.7 11 84.6 6 46.20 
2 6 46.2 12 92.3 2 15.4 0 0.00 
3 7 53.8 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 7 53.8 2=35.542 
p=0.000 
1 0 0.00 2 15.4 8 61.5 6 46.2 
2 5 38.5 10 76.9 5 38.5 0 0.00 
3 8 61.5 1 7.7 0 0.000 0 0.00 
Inter group comparison 
among the groups 








Table 7: Angamarda 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.0 0 0.0 0 0.0 1 7.7 2=33.393 
p=0.000 
1 0 0.00 0 0.00 8 61.5 10 76.9 
2 5 38.5 11 84.6 5 38.5 2 15.4 
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3 8 61.5 2 15.4 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 5 41.7 2=32.528 
p=0.000 
1 0 0.00 1 8.3 6 50.0 7 58.3 
2 4 33.3 9 75.0 6 50.0 0 0.00 
3 8 66.7 2 16.7 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 0 0.00 8 61.5 2=35.410 
p=0.000 
1 0 0.00 1 7.7 11 84.6 5 38.5 
2 6 46.2 12 92.3 2 15.4 0 0.00 
3 7 53.8 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 0 0.00 6 46.2 2=35.690 
p=0.000 
1 0 0.00 0 0.00 9 69.2 6 46.2 
2 5 38.5 11 84.6 4 30.8 1 7.7 
3 8 61.5 2 15.4 0 0.00 0 0.00  
 
 
Inter group comparison 
among the groups 









Table 8: Aruchi 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
 A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=33.491 
p=0.000 
1 0 0.00 0 0.00 4 30.8 10 76.9 
2 4 30.8 9 69.2 9 69.2 2 15.4 
3 9 69.2 4 30.8 0 0.00 0 0.00 
 B 0 0 0.00 0 0.00 0 0.00 3 25.0 2=35.292 
p=0.000 
1 0 0.00 0 0.00 6 50.0 6 50.0 
2 4 33.3 8 66.7 6 50.0 3 25.0 
3 8 66.7 4 33.3 0 0.00 0 0.00 
 C 0 0 0.00 0 0.00 0 0.00 9 69.2 2=36.328 
p=0.000 
1 0 0.00 3 23.1 8 61.5 4 30.8 
2 5 38.5 9 69.2 5 38.5 0 0.00 
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3 8 61.5 1 7.7 0 0.00 0 0.00 
 D 0 0 0.00 0 0.00 0 0.00 6 46.2 2=35.043 
p=0.000 
1 0 0.00 2 15.4 7 53.8 7 53.8 
2 5 38.5 10 76.9 6 46.2 0 0.00 
3 8 61.5 1 7.7 0 0.00 0 0.00 
Inter group comparison 
among the groups 











Table 9: Trishna 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=32.135 
p=0.000 
1 0 0.00 0 0.00 6 46.2 10 76.9 
2 6 46.2 10 76.9 6 46.2 2 15.4 
3 7 53.8 3 23.1 1 7.7 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 3 25.0 2=32.654 
p=0.000 
1 0 0.00 0 0.00 8 66.7 9 75.0 
2 4 33.3 9 75.0 4 33.3 0 0.00 
3 8 66.7 3 25.0 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 2 15.4 9 69.2 2=35.154 
p=0.000 
1 0 0.00 3 23.1 8 61.5 4 30.8 
2 6 46.2 9 69.2 3 23.1 0 0.00 
3 7 53.8 1 7.7 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 1 7.7 8 61.5 2=34.342 
p=0.000 
1 0 0.00 4 30.8 11 84.6 5 38.5 
2 7 53.8 8 61.5 1 7.7 0 0.00 
3 6 46.2 1 7.7 0 0.00 0 0.00 
Inter group comparison 
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Kruskal Wallis test 
Table 10: Alasya 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
 A 0 0 0.00 0 0.00 0 0.00 3 23.1 t =30.961 
p=0.000 
1 0 0.00 3 23.1 8 61.5 7 53.8 
2 6 46.2 8 61.8 4 30.8 3 23.1 
3 7 53.8 2 15.4 1 7.7 0 0.00 
 B 0 0 0.00 0 0.00 0 0.00 2 16.7 t =30.360 
p=0.000 
1 0 0.00 1 8.3 5 41.7 7 58.3 
2 5 41.7 8 66.7 7 58.3 3 25.0 
3 7 58.3 3 25.0 0 0.00 0 0.00 
 C 0 0 0.00 0 0.00 0 0.00 9 69.2 t =35.147 
p=0.000 
1 1 7.7 4 30.8 11 84.6 4 30.8 
2 4 30.8 6 46.2 2 15.4 0 0.00 
3 8 69.2 3 23.1 0 0.00 0 0.00 
 D 0 0 0.00 0 0.00 0 0.00 6 46.2 t =34.565 
p=0.000 
1 0 0.00 2 15.4 9 69.2 6 46.2 
2 4 30.8 9 69.2 4 30.8 1 7.7 
3 9 69.2 2 15.4 0 0.00 0 0.00  
Inter group comparison 
among the groups 










Table 11: Gaurav 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.00 0 0.00 0 0.00 0 0.00 2=32.215 
p=0.000 
1 0 0.00 0 0.00 4 30.8 11 84.6 
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2 4 30.8 10 76.9 9 69.2 2 15.4 
3 9 69.2 3 23.1 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 3 25.0 2=30.240 
p=0.000 
1 0 0.00 1 8.3 4 33.3 6 50.0 
2 4 33.3 8 66.7 8 66.7 3 25.0 
3 8 66.7 3 25.0 0 0.00 0 0.00 
C 0 0 0.00 0 0.00 2 15.4 10 76.9 2=305.462 
p=0.000 
1 0 0.00 2 15.2 9 69.2 3 23.1 
2 7 53.8 11 84.6 2 15.4 0 0.00 
3 6 46.2 0  0 0.00 0 0.00 
D 
 
0 0 0.00 0 0.00 1 7.7 6 46.2 2=33.956 
p=0.000 
1 0 0.00 2 15.4 8 61.5 7 53.8 
2 6 46.2 10 76.9 4 30.8 0 0.00 
3 7 53.8 1 7.7 0 0.00 0 0.00 
Inter group comparison 
among the groups 










Table 12: Jwara 
Group  Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=29.909 
P=0.000 
1 0 0.00 3 23.1 6 46.2 10 76.9 
2 6 46.2 8 61.5 6 46.2 2 15.4 
3 7 53.8 2 15.4 1 7.7 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 3 25.0 2=29.722 
P=0.000 
1 0 0.00 4 33.3 7 58.3 9 75.0 
2 8 66.7 8 66.7 5 41.7 0 0.00 
3 4 33.7 0 0.00 0 0.00 0 0.00 
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C 0 0 0.00 1 7.7 6 46.2 9 69.2 2=31.660 
P=0.000 
1 2 15.4 8 61.5 6 46.2 4 30.8 
2 8 61.5 4 30.8 1 7.7 0 0.00 
3 3 23.1 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 1 7.7 4 30.8 2=31.800 
p=0.00 
1 0  5 38.5 9 69.2 9 69.2 
2 8 61.5 7 53.8 3 23.1 0 0.00 
3 5 38.5 1 7.7 0 0.00 0 0.00 
Inter group comparison 
among the groups 









Table 13: Apaka 
Group Score BT F1 F2 AT Within the group 
comparison 
Friedman Test No. of pt. % No. of pt. % No. of pt. % No. of pt. % 
A 0 0 0.00 0 0.00 0 0.00 1 7.7 2=30.083 
p=0.000 
1 0 0.00 2 15.4 5 38.5 10 76.9 
2 6 46.2 9 69.2 8 61.5 2 15.4 
3 7 53.8 2 15.4 0 0.00 0 0.00 
B 0 0 0.00 0 0.00 0 0.00 4 33.3 2=25.105 
p=0.000 
1 1 8.3 6 50.0 8 66.7 6 50.0 
2 7 58.3 3 25.0 3 25.0 2 16.7 
3 4 33.3 3 25.0 1 8.3 0 0.00 
C 0 0 0.00 1 7.7 6 46.2 10 76.9 2=31.088 
p=0.000 
1 6 46.2 10 76.9 7 53.8 3 23.1 
2 7 53.8 2 15.4 0 0.00 0 0.00 
3 0 0.00 0 0.00 0 0.00 0 0.00 
D 0 0 0.00 0 0.00 4 30.8 8 61.5 2=31.702 
p=0.000 
1 4 30.8 10 76.9 9 69.2 5 38.5 
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2 7 53.8 3 23.1 0 0.00 0 0.00 
3 2 15.4 0 0.00 0 0.00 0 0.00 
Inter group comparison 
among the groups 









Table 14: Anti CCP  
Group Anti CCP 
Mean ± SD 
Within the group comparison  
Wilcoxon Signed Rank test 
BT AT 
A 76.55±160.088 70.33±146.357 Z=-2.758, P=0.006 
B 74.94±163.620 49.97±93.868 Z=-2.293, P=0.022 
C 131.03±140.061 87.62±98.557 Z=-3.111, P=0.002 
D  52.86±13.356 26.41±7.419 Z=-3.181, P=0.001 
Between the group comparison 






Table 15: RA test 
Group RA Mean ± SD Within the group comparison  
Wilcoxon Signed Rank test 
BT AT 
A 59.70±109.735 57.883±106.7949 Z=-1.992, P=0.046 
B 64.36±39.344 45.208±22.3579 Z=-2.347, P=0.019 
C 80.42±46.740 69.262±83.1046 Z=-2.040, P=0.041 
D  77.77±16.146 47.308±18.7189 Z=-3.184, P=0.001 
Between the group comparison 






Table 16: EULAR  
Group EULAR Mean±SD Within the group comparison  
Paired t test  (BT-AT) 
BT AT 
A 8.31±1.182 6.77±0.725 t=6.325, P=0.000 
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B 7.92±1.379 5.83±1.030 t=10.795, P=0.000 
C 7.62±1.446 5.15±1.068 t=10.119, P=0.000 
D  7.46±1.330 5.31±1.032 t=8.641, P=0.000 
Between the group comparison 






Post Hoc Test 
A vs C  P=0.001  
A vs D  P=0.002  
 
DISCUSSION  
Relief in pain may be due to Ushnavirya property of 
drug like Shunthi, Guduchi, Trivrit help in Ama pachan, 
thereby reducing pain. This may be due to decreased 
PGE2 release inside the joint space. Reliefin Swelling 
may be due to drug like Vibhitaki, Haritaki, Guduchi 
having Ushnavirya property, thereby reducing the 
swelling. This relief in swelling may be due to 
inhibition of IL-1, IL-6 and TNF-α. Relief in Joint 
stiffness occurs due to predominance of Vata Dosha. 
Therefore Vatahara drug like Trivit, Shunthi having 
Ushna property, thereby reducing joint stiffness. 
Morning stiffness is the common manifestation in RA. 
After receiving treatment by the patients there will be 
reduction in joint stiffness, thereby enhancing the 
walking time. As per Ayurvedic text, Vasti is said to be 
the major procedure to reduce Vata and stiffness is 
mainly related to Vata Dosha. That is why those 
patients who receive Vasti show better result. 
Administration of Vasti pacified Vata Dosha, thereby 
enhancing grip power. Ama is the causative factor of 
Amavata. Kaphahara property of drug like Amalaki, 
Vibhitaki reduces the Ama and hence get relief from 
Angamarda. Aruchi occurs due to vitiation of Kapha 
Dosha. After receiving treatment by Ushna Virya 
property like Shunthi, Vibhitaki produce Ruchikar 
effect. Relief in Trishna due to Vata Pitta Dosha. In 
order to reduce the Trishna drug like Lajjalu, Gokshur 
having Shitavirya property and Vata Pitta Shamak 
nature they reduces Trishana. Relief in Alasya due to 
Kapha Dosha. After receiving treatment by Ushnavirya  
 
drug like Shunthi, Guduchi reduces Kapha Dosha and 
ultimately reduces Alasya. Gaurav occurs due to Ama 
Dosha. After receiving treatment by Ushna Virya drug 
like Shunthi, Guduchi, Trivrit reduces Ama Dosha and 
ultimately reduces Gaurav. There was a significant 
reduction in Anti CCP in both groups. It may be due to 
reduction in inflammation of disease. Macrophage 
migration inhibitory factor (MIF) and vascular 
endothelial growth factor, as crucial parameter of 
angiogenesis and inflammation, were evaluated to 
identify the role of cyclic citrullinated peptic 
antibodies (Anti ccp) during angiogenesis in 
rheumatoid arthritis.[8,9] There was a significant 
reduction in RA factor titre in both groups. It may be 
due to breaking of pathogenesis of disease by Dipana 
and Pachana property of Alambhushadi Churna. 
Serum IgM RF has been found in 75-80% of patients 
with RA; therefore, a negative result does not exclude 
the presence of disease. It is also found in other 
connective tissue, such as primary Sjogrens systemic 
lupus erythematosus, Hepatitis B and C and in chronic 
infection.[10] Also there was a significant reduction in 
EULAR in both groups. Ingredients of Alambhushadi 
Churna are Alambhusha (Lajjalu), Gokshur, Haritaki, 
Bibhitaki, Amalaki, Shunthi, Amrita, Trivrutta in the 
having highest concentration of Trivrutta with their 
Kapha Vata Shamaka and Virechan properties thus 
help in reducing the swelling in the joints. All the 
properties of the drugs of Alambushadi Churna, Ama 
and Vata Dosha is treated and thus relief in the 
cardinal symptoms of the disease was found. Guduchi 
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is also proved to have antirheumatic, anti-
inflammatory, and immunomodulatory properties. 
Sunthi is beneficial for rheumatic and musculoskeletal 
disorders. Provide relief from pain and swelling 
Shunthi with its Ushnavirya help in digestion of Ama 
and improve the Agni. Triphala has Rasayana, 
Tridoshahara and Virechana properties which helps in 
reducing the swelling in the joints. Trivrit is considered 
best among laxative drug. The laxative effect of Trivrit 
is mainly due to the presence of turpentine. Gokshuru 
with its diuretic property help in reducing the swelling 
of joints. Also it is Vata and Kapha Shamaka.[11]. 
Dwipanchmuladya Taila Matra Basti is the type of 
Sneha Basti described in Bhav Prakash Amavata 
Chikitsa. As a whole the qualities of Matra Basti can 
be considered as Laghu, Snigdha, Ushna, Tikshna. 
Majority of the drugs are having Vata-Kapha Shamaka 
action. Owing to this property, antagonism to Kapha 
and Ama the Basti help in significant improvement in 
sign and symptom of disease. 
CONCLUSION 
Disease Amavata can be correlated to Rheumatoid 
Arthritis, which is one among the chronic destructive 
polyarthritic systemic disease. The exact aetiology of 
the disease remains unknown, but the pathognomic 
Nidana like Ama is believed to be acts as autoantigen, 
which triggers the immunological reaction in 
genetically susceptible individuals. The sign and 
symptoms e.g., Loss of appetite, Angamarda, Alasya 
etc. due to derangement of Aam are observed to be 
improved in by Alambushadi Churna oral & 
Matravasti regime as compared to Methotrexate. 
There was neither any side effect produced nor any 
side effect observed during the trial drug therapy. We 
have observed that in group C oral intake of 
Alambushadi Churna and Matravasti by 
Dwipanchmuladhya Taila is effective in treating all the 
sign and symptoms and other associated Lakshanas of 
the disease. 
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